Compare AU
Compare HLTH vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the MarketGrader Developed Markets (ex-AUS) Health Care ETF (HLTH) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HLTH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 62 | 81 |
Median incremental investment | $545.10 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,445.12 | $1,386.00 |
Average age group | > 35 | > 35 |
Key Summary
HLTH | CURE | |
|---|---|---|
Strategy | HLTH.AX was created on 2020-09-08 by VanEck. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investment returns before fees and other costs which track the performance of the Reference Index in Australian dollars. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Exelixis Inc (2.83 %) DexCom Inc (2.56 %) Waters Corp (2.54 %) | Neurocrine Biosciences Inc (2.58 %) AbbVie Inc (2.42 %) Gilead Sciences Inc (2.42 %) |
Top 3 industries | Health Care (100.00 %) Other (9.88 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (68.78 %) Japan (13.50 %) Denmark (7.34 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
HLTH | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | MarketGrader Developed Markets ex-Australia Health Care Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $11.29 | $49.49 |
Size | $49.880 million | $36.399 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.58 % | 4.24 % |
Market | ASX | ASX |
First listed date | 09/09/2020 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HLTH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 62 | 81 |
Median incremental investment | $545.10 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,445.12 | $1,386.00 |
Average age group | > 35 | > 35 |
Pros and Cons
HLTH | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HLTH | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |